Plain-English translation of NCT07187063 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
After treatment for early-stage bladder cancer, patients typically need frequent cystoscopy procedures (camera exams of the bladder) to watch for cancer returning. This study tests whether a urine DNA test — which looks for cancer cells in urine — can accurately predict which patients are safe and can have fewer of these routine check-ups. If successful, this could mean less frequent, less invasive monitoring for some patients.
Frequent cystoscopy procedures can be uncomfortable and time-consuming for patients. This trial exists to see if the urine DNA test is reliable enough to safely reduce the number of these procedures some patients need, while still catching any cancer that returns early.
You likely qualify if…
You likely don't qualify if…
You will be assigned to either the standard surveillance group (regular cystoscopy check-ups as usual) or the de-intensified group (fewer cystoscopy visits, guided by urine DNA test results). Both groups will provide urine samples regularly so researchers can track whether the urine DNA test accurately predicts who stays cancer-free. Your doctor will monitor you closely either way to ensure your safety.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States
Sponsor
Lahey Clinic
Enrollment target
~56 participants
Started
January 2025
Primary completion
January 2029
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Linda Topjian
Lahey Hospital & Medical Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.